OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Therapeutic options for PD-1 refractory skin cancer 3 Jan – 6PM BST | 1PM EDT | 10AM PDT Allison Betof Warner, Omid Hamid, Inderjit Mehmi…
Benjamin Rolles, MD, Brigham and Women’s Hospital, Boston, MA, comments on the results of an analysis from the International Consortium for MDS (icMDS) VALIDATE Database,…
Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.
VJHemOnc is excited to share a feature covering the late-breaking abstracts presented at the 66th ASH Annual Meeting & Exposition.
T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.
Aaron Gerds, MD, discusses data from the SIMPLIFY-1 and MOMENTUM trials which support the use of momelotinib in myelofibrosis with anemia.
Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.
Full of stamina and determination, Lynn Lippert supported others and did what she loved through 24 years of living with metastatic breast cancer. Lippert’s life…
Art remains a vital part of Fox Chase Cancer Center’s culture. From the symbolic sculpture, The Diamond, greeting visitors outside the main entrance to the…